Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis

de Pont, Anne Cornélie J. M.; Bouman, Catherine S. C.; de Jonge, Evert; Vroom, Margreeth B.; Büller, Harry R.; Levi, Marcel; de Pont, Anne Cornélie J M; Büller, Harry R
July 2003
Intensive Care Medicine;Jul2003, Vol. 29 Issue 7, p1205
Academic Journal
Presents a letter to the editor focusing on the treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis.


Related Articles

  • Monitoring the Direct Thrombin Inhibitors. FRITSMA, GEORGE A. // Clinical Laboratory Science;Winter2013, Vol. 26 Issue 1, p54 

    No abstract available.

  • Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. Bernard, Gordon R.; Vincent, Jean-Louis; Laterre, Pierre-Francois; LaRosa, Steven P.; Dhainaut, Jean-Francois; Lopez-Rodriguez, Angel; Steingrub, Jay S.; Garber, Gary E.; Helterbrand, Jeffrey D.; Ely, E. Wesley; Fisher, Charles J. // New England Journal of Medicine;03/08/2001, Vol. 344 Issue 10, p699 

    Background: Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in...

  • Increasing evidence that the risks of rhAPC may outweigh its benefits. Eichacker, Peter Q.; Natanson, Charles // Intensive Care Medicine;Mar2007, Vol. 33 Issue 3, p396 

    The article analyzes the risks and benefits of the use of recombinant human activated protein C (rhAPC) to control severe sepsis. Surveys conducted since the approval of rhAPC in 2001 found that the risk of bleeding during clinical use might be greater than was observed in the original phase-3...

  • Proteases: Unravelling the therapeutic activity of activated protein C. Flight, Monica Hoyos // Nature Reviews Drug Discovery;Jan2010, Vol. 9 Issue 1, p20 

    The article discusses the therapeutic effect of activated protein C (APC) in diseases such as amyotrophic lateral sclerosis (ALS) and sepsis. It notes that recombinant APC treats sepsis though its therapeutic activity is poorly understood. Study shows that the infusion of APC or antibodies...

  • 'Bleeding Avoidance Strategies' and PCI. Boyle, Andrew J. // Clinical Cardiology Alert;Aug2010, Vol. 29 Issue 8, p57 

    ACCESS-SITE BLEEDING IS ONE OF THE MAJOR COMPLICATIONS OF PERCUTANEOUS coronary intervention (PCI). It is associated with the need for blood transfusions, increased length of stay, and increased healthcare expenditure. Strategies to reduce access-site bleeding may have the ability to improve...

  • Thanks a clot.  // Men's Health;May97, Vol. 12 Issue 4, p144 

    Provides information about an anticoagulant, clopidogrel's effectivity in preventing recurrences of heart attack and stroke. Advantage of clopidogrel compared to aspirin.

  • Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. XIAO-LI LIU; XIAO-ZHI WANG; XIU-XING LIU; DONG HAO; YASAMAN JALADAT; FENG LU; TING SUN; CHANG-JUN LV // Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 3, p604 

    The present study aimed to investigate whether low-dose heparin improves the condition of patients suffering from early disseminated intravascular coagulation (pre-DIC) during sepsis. In total, 37 patients were randomly divided into low-dose heparin intervention and control groups. The heparin...

  • Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents. Franchini, Massimo; Lippi, Giuseppe // Current Vascular Pharmacology;Apr2007, Vol. 5 Issue 2, p121 

    Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel...

  • Novel anticoagulants in prevention and treatment of venous thromboembolism. Cosmi, Benilde // Hot Topics in Cardiology;2012, Vol. 7 Issue 29, p13 

    Venous thromboembolism (VTE) encompassing deep vein thrombosis and its potentially fatal complication, pulmonary embolism, are frequent conditions and the third cause of cardiovascular death. The limitations of available anticoagulants for VTE prevention and treatment have spurred the search for...

  • Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. Jones, G. Morgan; Twilla, Jennifer D.; Hoit, Daniel A.; Arthur, Adam S. // Journal of NeuroInterventional Surgery;Sep2013, Vol. 5 Issue 5, p1 

    Prevention of intracranial stent thrombosis with dual-antiplatelet therapy is widely used in neuroendovascular procedures. However, the rising incidence of inadequate platelet inhibition with clopidogrel may increase complications following stent placement, especially with newer devices that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics